Participants 34 102 6
patients receiving androgen deprivation therapy for prostate cancer.
Participants 185 210 3
advanced prostate cancer,
Participants 356 410 4
patients with prostate cancer during androgen ablation
Participants 753 849 6
Forty-eight osteoporotic patients with prostate cancer, treated with 3-month depot triptorelina,
